Diabetic Kidney Disease

Diabetic Kidney Disease

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group
N Engl J Med. 2017 Jun 12. doi: 10.1056/NEJMoa1611925
Google Plus
LinkedIn

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920
Google Plus
LinkedIn

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Linda F. Fried, M.D., M.P.H., Nicholas Emanuele, M.D., Jane H. Zhang, Ph.D., Mary Brophy, M.D., Todd A. Conner, Pharm.D., William Duckworth, M.D., David J. Leehey, M.D., Peter A. McCullough, M.D., M.P.H., Theresa O'Connor, Ph.D., Paul M. Palevsky, M.D., R
N Engl J Med 2013; 369:1892-1903November 14, 2013
Google Plus
LinkedIn

Effects of intensive blood-pressure control in type 2 diabetes mellitus

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F
N Engl J Med. 2010 Apr 29;362(17):1575-85
Google Plus
LinkedIn

Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years’ Duration

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ
Arch Intern Med. 2009 Jul 27;169(14):1307-16
Google Plus
LinkedIn

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan
N Engl J Med. 2008 Jun 12;358(24):2560-72
Google Plus
LinkedIn

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B
Lancet. 2007 Sep 8;370(9590):829-40
Google Plus
LinkedIn

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Edmund J. Lewis, M.D., Lawrence G. Hunsicker, M.D., William R. Clarke, Ph.D., Tomas Berl, M.D., Marc A. Pohl, M.D., Julia B. Lewis, M.D., Eberhard Ritz, M.D., Robert C. Atkins, M.D., Richard Rohde, B.S., and Itamar Raz, M.D., for the Collaborative Study G
N Engl J Med. 2001 Sep 20;345(12):851-60
Google Plus
LinkedIn

Suggest an Article or Abstract

For suggested articles, Simply enter an article's PubMed ID number and our reviewers will consider the article for addition to the archive. Otherwise, attach a PDF below. You may also submit a visual abstract for consideration

Or
Add files